Letrozole Eugia

Letrozole, the active ingredient in Letrozole Eugia, is an aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen levels, which can slow the growth of estrogen‑dependent tumors.

GNH USA supplies Letrozole Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letrozole Eugia is used in the management of estrogen‑dependent breast cancer, primarily in postmenopausal patients. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces estrogen production to inhibit tumor growth. - Metastatic breast cancer (postmenopausal): Delays disease progression and improves survival. - Adjuvant therapy after surgery (postmenopausal): Decreases risk of cancer recurrence.

Letrozole may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Joint and muscle pain: Arthralgia or myalgia affecting daily activities. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach. - Headache: Intermittent pressure or throbbing pain. - Dizziness: Light‑headed sensation, especially when standing quickly.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, dark urine, elevated liver enzymes. - Bone fracture: Increased risk due to reduced bone mineral density. - Deep vein thrombosis or pulmonary embolism: Swelling, pain, or shortness of breath. - Severe allergic reaction: Rash, swelling, or difficulty breathing. - Elevated cholesterol: Significant changes in lipid profile.

When prescribing Letrozole Eugia, several safety considerations should be observed. - Pregnancy contraindication: Do not use in pregnant women; teratogenic risk (Category X). - Bone health monitoring: Assess bone mineral density periodically during therapy. - Liver function: Monitor hepatic enzymes regularly. - Lipid profile: Check cholesterol levels as alterations may occur. - Avoid in premenopausal women: Ineffective and may increase estrogen levels. - Store at ambient temperature: Keep in original container, protect from moisture.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Estrogen replacement therapy: Counteracts letrozole’s estrogen‑lowering effect. - Tamoxifen: Antagonistic action reduces therapeutic benefit. - Strong CYP2A6 inhibitors (e.g., ketoconazole): May increase letrozole exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): May lower plasma concentrations of letrozole. - Warfarin: Potential alteration of INR; monitor coagulation status. - Statins: Possible increased risk of myopathy; observe for muscle symptoms.